Alzheimer’s vaccine
April 27, 2010
A VACCINE for Alzheimer’s
disease could be confirmed for
efficacy as early as 2012, with
reports surfacing that AFFiRiS AG’s
clinical Alzheimer’s vaccine
candidate AD02 has already
progressed to phase II trials.
A total of 420 patients from
Austria, Germany, France, the
Czech Republic, Slovakia and
Croatia are currently being recruited
for the phase II trial, which will
focus on the vaccine’s efficacy.
“Last year AD02, along with our
second prospective Alzheimer’s
vaccine AD01, was primarily tested
in terms of its safety and tolerability.
“Those primary endpoints have
been met by vaccine formulations,”
said AFFiRiS AG’s ceo, Dr Walter
Schmid.
“The decision to nominate AD02
for phase II testing study is based
on currently still confidential results
of the interim analysis of the
secondary endpoints of the
preceding phase I studies,” he
added.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Apr 10To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Apr 10
